The cost‐effectiveness of outpatient (at home) cervical ripening with isosorbide mononitrate prior to induction of labour

Abstract

Although the probability that IMN is cost-effective approaches 0.7 at seemingly low willingness to pay thresholds for an hour prevented from hospital admission to delivery, our results should be viewed in the light of the clinical findings from the IMOP trial.